162 related articles for article (PubMed ID: 31167516)
1. Serum Levels of Interleukin-6 and Titers of Antibodies Against
Park DG; Woo BH; Lee BJ; Yoon S; Cho Y; Kim YD; Park HR; Song JM
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31167516
[TBL] [Abstract][Full Text] [Related]
2. About a Possible Impact of Endodontic Infections by
Ciani L; Libonati A; Dri M; Pomella S; Campanella V; Barillari G
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791123
[TBL] [Abstract][Full Text] [Related]
3. Periodontal pathogens promote cancer aggressivity via TLR/MyD88 triggered activation of Integrin/FAK signaling that is therapeutically reversible by a probiotic bacteriocin.
Kamarajan P; Ateia I; Shin JM; Fenno JC; Le C; Zhan L; Chang A; Darveau R; Kapila YL
PLoS Pathog; 2020 Oct; 16(10):e1008881. PubMed ID: 33002094
[TBL] [Abstract][Full Text] [Related]
4. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality.
Ahn J; Segers S; Hayes RB
Carcinogenesis; 2012 May; 33(5):1055-8. PubMed ID: 22367402
[TBL] [Abstract][Full Text] [Related]
5. Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by stimulating the release of neutrophil extracellular traps in the tumor immune microenvironment.
Guo ZC; Jing SL; Jia XY; Elayah SA; Xie LY; Cui H; Tu JB; Na SJ
Inflamm Res; 2024 May; 73(5):693-705. PubMed ID: 38150024
[TBL] [Abstract][Full Text] [Related]
6. Porphyromonas gingivalis suppresses oral squamous cell carcinoma progression by inhibiting MUC1 expression and remodeling the tumor microenvironment.
Lan Z; Zou KL; Cui H; Zhao YY; Yu GT
Mol Oncol; 2024 May; 18(5):1174-1188. PubMed ID: 37666495
[TBL] [Abstract][Full Text] [Related]
7. Prevotella intermedia boosts OSCC progression through ISG15 upregulation: a new target for intervention.
Qin Y; Li Z; Liu T; Ma J; Liu H; Zhou Y; Wang S; Zhang L; Peng Q; Ye P; Duan N; Wang W; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):206. PubMed ID: 38644421
[TBL] [Abstract][Full Text] [Related]
8. Association of DOK3 and infiltrated tumor-associated macrophages with risk for the prognosis of Porphyromonas gingivalis-infected oral cancer: a 12-year data analysis of 200 patients from a tertiary teaching hospital, Urumqi, China.
Li C; Li M; Wei W; Wang Z; Yu J; Gong Z
BMC Cancer; 2024 Apr; 24(1):534. PubMed ID: 38671413
[TBL] [Abstract][Full Text] [Related]
9. Persistent infection with Porphyromonas gingivalis increases the tumorigenic potential of human immortalised oral epithelial cells through ZFP36 inhibition.
Lu Z; Cao R; Geng F; Pan Y
Cell Prolif; 2024 Jun; 57(6):e13609. PubMed ID: 38351596
[TBL] [Abstract][Full Text] [Related]
10. Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment.
Guo ZC; Jing SL; Jumatai S; Gong ZC
Cancer Immunol Immunother; 2023 Jun; 72(6):1523-1539. PubMed ID: 36513851
[TBL] [Abstract][Full Text] [Related]
11. The Roles and Interactions of
Wang B; Deng J; Donati V; Merali N; Frampton AE; Giovannetti E; Deng D
Pathogens; 2024 Jan; 13(1):. PubMed ID: 38276166
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of Porphyromonas gingivalis-derived phosphoethanolamine dihydroceramide on acid ceramidase expression in oral squamous cells.
Yamada C; Ho A; Nusbaum A; Xu R; Davey ME; Nichols F; Mao C; Movila A
J Cell Mol Med; 2023 May; 27(9):1290-1295. PubMed ID: 37016912
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicles from Aggregatibacter actinomycetemcomitans exhibit potential antitumorigenic effects in oral cancer: a comparative in vitro study.
Metsäniitty M; Hasnat S; Öhman C; Salo T; Eklund KK; Oscarsson J; Salem A
Arch Microbiol; 2024 May; 206(6):244. PubMed ID: 38702412
[TBL] [Abstract][Full Text] [Related]
14. Co-Culture of
Yáñez L; Soto C; Tapia H; Pacheco M; Tapia J; Osses G; Salinas D; Rojas-Celis V; Hoare A; Quest AFG; Díaz-Elizondo J; Pérez-Donoso JM; Bravo D
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612423
[TBL] [Abstract][Full Text] [Related]
15. Acetylshikonin suppresses invasion of Porphyromonas gingivalis‑infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis.
Cho BH; Jung YH; Kim DJ; Woo BH; Jung JE; Lee JH; Choi YW; Park HR
Mol Med Rep; 2018 Feb; 17(2):2327-2334. PubMed ID: 29207110
[TBL] [Abstract][Full Text] [Related]
16. Frequencies of
Kong J; Yuan X; Wang J; Liu Y; Sun W; Gu B; Lan Z; Gao S
Pathol Oncol Res; 2021; 27():628942. PubMed ID: 34257592
[TBL] [Abstract][Full Text] [Related]
17. Salivary and Serum Interleukin-6: A Credible Marker for Predicting Oral Leukoplakia and Oral Squamous Cell Carcinoma by Enzyme-Linked Immunosorbent Assay (ELISA).
Oshin M; Kulkarni PG; D SPR; Deepthi G; S KS; S JK
Cureus; 2024 Apr; 16(4):e59113. PubMed ID: 38803729
[TBL] [Abstract][Full Text] [Related]
18. Potential role of epithelial-mesenchymal transition induced by periodontal pathogens in oral cancer.
Ma Y; Yu Y; Yin Y; Wang L; Yang H; Luo S; Zheng Q; Pan Y; Zhang D
J Cell Mol Med; 2024 Jan; 28(1):e18064. PubMed ID: 38031653
[TBL] [Abstract][Full Text] [Related]
19. Identification of bio-active secondary metabolites from Actinobacteria as potential drug targets against
Taj Z; Chattopadhyay I
In Silico Pharmacol; 2024; 12(1):34. PubMed ID: 38666247
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Association Between Fusobacterium nucleatum and Oral Squamous Cell Carcinoma: A Pilot Case-Control Study on Tissue Samples.
Kaliamoorthy S; Priya Sayeeram S; SundarRaj S; Balakrishnan J; Nagarajan M; Samidorai A
Cureus; 2023 Oct; 15(10):e47238. PubMed ID: 38022043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
